Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GSK587323 (Candesartan/HCTZ) vs Atacand D in Healthy Volunteers
NCT02094924Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candesartan cilexetil and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by GSK. Primary endpoint: Composite of PK parameters for candesartan and HCTZ. Started Apr 2014; status: completed.
02
Drugs
candesartan cilexetilhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02094924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094924.